Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

BACKGROUND: Psoriasis is a chronic inflammatory skin disease requiring prolonged treatment. New biologic therapies require long‐term evaluation to assess the durability of their efficacy and safety profiles over time. OBJECTIVES: To evaluate the long‐term efficacy and safety of risankizumab (RZB) fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, K.A., Lebwohl, M.G., Puig, L., Ohtsuki, M., Beissert, S., Zeng, J., Rubant, S., Sinvhal, R., Zhao, Y., Soliman, A.M., Alperovich, G., Leonardi, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290992/
https://www.ncbi.nlm.nih.gov/pubmed/34157132
http://dx.doi.org/10.1111/bjd.20595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290992/
https://www.ncbi.nlm.nih.gov/pubmed/34157132
http://dx.doi.org/10.1111/bjd.20595

Ejemplares similares